WHO experts recommend the use of Takeda’s dengue vaccine QDENGA

In­tra-Cel­lu­lar Ther­a­pies’ Caply­ta sig­nif­i­cant­ly im­proved symp­toms in a late-stage ma­jor de­pres­sive dis­or­der tri­al, mark­ing a step in the drug’s jour­ney to be­com­ing a pipeline-in-a-pill. Atyp­i­cal

Tezspire is a thymic stromal lymphopoietin (TSLP) inhibiting monoclonal antibody, which generated $86m in sales in 2023. Image credit: eamesBot / Shutterstock. AstraZeneca and Amgen